Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Post by Golddetectoron Oct 15, 2021 7:58am
373 Views
Post# 34008401

Major short term milestones

Major short term milestones

Below are the major milestones expected this Q
1. Reduvo DIN. Big item it will make tetra revenue generating pharma.

2. QIXLEEF reborn1 interim results report. This is very important. Although recent highlighted positive results but this will discuss details. Note that Tbp will market QIXLEEF based on reborn 1 based on latest info and won't wait for reborn 2. Check the details on news release of using fast track path. Note also another site was added late august so we have two sites now. 


3. QIXLEEF plenitude interim report. These results will be required for the fast track fda approval.

There are 3 more listed in the latest management discussions but I presented the big one only above.

good luck guys 

<< Previous
Bullboard Posts
Next >>